8-K filing — InMed Pharmaceuticals Inc. (INM)
Filed: 2026-07-22 AccNo: 0001213900-26-080414 Size: 303 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Mentari Therapeutics shares are trading higher after the company announced a $200 million private placement to healthcare investors.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 22, 2026, 2:36 PM
- Checked
- Jul 22, 2026, 2:36 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.
Read original at benzingaInMed Pharmaceuticals Regains Nasdaq Compliance
Read original at benzinga